Allianz Asset Management Gmb H Mirati Therapeutics, Inc. Transaction History

Allianz Asset Management Gmb H

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$39.16 - $88.71 $765,773 - $1.73 Million	19,555 Added 129.37%	34,670 $2.33 Million
Q1 2022 May 13, 2022	SELL	$75.82 - $150.97 $630,215 - $1.25 Million	-8,312 Reduced 35.48%	15,115 $1.24 Million
Q4 2021 Feb 11, 2022	SELL	$132.01 - $190.29 $1.19 Million - $1.71 Million	-8,994 Reduced 27.74%	23,427 $3.44 Million
Q3 2021 Nov 10, 2021	BUY	$132.13 - $177.45 $1.16 Million - $1.55 Million	8,747 Added 36.95%	32,421 $5.74 Million
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $20,592 - $25,701	143 Added 0.61%	23,674 $3.82 Million

Q1 2021 May 13, 2021	SELL	$158.92 - $221.61 $272,229 - $379,617	-1,713 Reduced 6.79%	23,531 $4.03 Million
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $456,008 - $676,119	2,814 Added 12.55%	25,244 $5.54 Million
Q3 2020 Nov 13, 2020	BUY	$113.26 - $167.27 $13,930 - $20,574	123 Added 0.55%	22,430 $3.73 Million
Q2 2020 Aug 14, 2020	BUY	$72.01 - $120.39 $858,431 - $1.44 Million	11,921 Added 114.78%	22,307 $2.55 Million
Q1 2020 May 14, 2020	SELL	$69.78 - $116.21 $1.63 Million - $2.71 Million	-23,321 Reduced 69.19%	10,386 $799,000
Q4 2019 Feb 13, 2020	BUY	$70.76 - $128.86 $1.77 Million - $3.22 Million	24,966 Added 285.62%	33,707 $4.34 Million
Q3 2019 Nov 13, 2019	BUY	$77.91 - $109.6 $6,076 - $8,548	78 Added 0.9%	8,741 $697,000
Q2 2019 Aug 08, 2019	SELL	$59.49 - $104.71 $1.59 Million - $2.8 Million	-26,701 Reduced 75.5%	8,663 $892,000
Q1 2019 May 13, 2019	BUY	$43.65 - $78.95 $1.54 Million - $2.79 Million	35,364 New	35,364 $2.59 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.